| Anne Kim, DDS | |
|
1711 Atlantic Ave, Long Beach, CA 90813-2018 | |
| (562) 591-4028 | |
| (562) 591-5878 |
| Full Name | Anne Kim |
|---|---|
| Gender | Female |
| Speciality | Dentist - General Practice |
| Location | 1711 Atlantic Ave, Long Beach, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619450715 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | DDS102900 (California) | Primary |
| Entity Name | Tsibel Dental Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851589329 PECOS PAC ID: 6800224668 Enrollment ID: O20200310002794 |
News Archive
A study by researchers at the Mailman School of Public Health evaluated the impact of text messaging reminders for influenza vaccine in a low-income obstetric population. The findings showed that sending text messages to this population of women resulted in an uptick in influenza vaccination, especially for those who received the messages early in their third trimester.
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Restanza(TM) (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Both tularemia and plague are classified by the Centers for Disease Control as Category A Bioterrorism Agents, which is the highest priority classification.
An anti-inflammatory drug called roflumilast could become a new therapeutic strategy for patients with chronic obstructive pulmonary disease (COPD), conclude the results of a randomised trial in this week's issue of The Lancet.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.
Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.
› Verified 2 days ago
| Entity Name | Tsibel Dental Practice Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053893271 PECOS PAC ID: 1557604931 Enrollment ID: O20200311000565 |
News Archive
A study by researchers at the Mailman School of Public Health evaluated the impact of text messaging reminders for influenza vaccine in a low-income obstetric population. The findings showed that sending text messages to this population of women resulted in an uptick in influenza vaccination, especially for those who received the messages early in their third trimester.
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Restanza(TM) (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Both tularemia and plague are classified by the Centers for Disease Control as Category A Bioterrorism Agents, which is the highest priority classification.
An anti-inflammatory drug called roflumilast could become a new therapeutic strategy for patients with chronic obstructive pulmonary disease (COPD), conclude the results of a randomised trial in this week's issue of The Lancet.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.
Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anne Kim, DDS 1711 Atlantic Ave, Long Beach, CA 90813-2018 Ph: (562) 591-4028 | Anne Kim, DDS 1711 Atlantic Ave, Long Beach, CA 90813-2018 Ph: (562) 591-4028 |
News Archive
A study by researchers at the Mailman School of Public Health evaluated the impact of text messaging reminders for influenza vaccine in a low-income obstetric population. The findings showed that sending text messages to this population of women resulted in an uptick in influenza vaccination, especially for those who received the messages early in their third trimester.
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Restanza(TM) (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Both tularemia and plague are classified by the Centers for Disease Control as Category A Bioterrorism Agents, which is the highest priority classification.
An anti-inflammatory drug called roflumilast could become a new therapeutic strategy for patients with chronic obstructive pulmonary disease (COPD), conclude the results of a randomised trial in this week's issue of The Lancet.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.
Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.
› Verified 2 days ago
Dr. Vincent Do, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 324 E Anaheim St, Ste C, Long Beach, CA 90813 Phone: 562-435-8100 | |
Mark T Arima, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 2535 Pacific Ave, Long Beach, CA 90806 Phone: 562-424-5050 Fax: 562-997-0537 | |
Michael M. Le, D.D.S Dentist Medicare: Not Enrolled in Medicare Practice Location: 2150 E South St, Ste. 116, Long Beach, CA 90805 Phone: 562-531-9779 Fax: 562-531-9779 | |
Dr. Celso Sy, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 3601 Elm Ave, Long Beach, CA 90807 Phone: 562-427-8833 Fax: 562-394-0965 | |
Howard Morton Polk Iii, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 5901 E 7th St, Long Beach, CA 90822 Phone: 562-826-8000 | |
Dr. Maged Zaky Nessim, D.D.S.,INS Dentist Medicare: Not Enrolled in Medicare Practice Location: 3440 Atlantic Ave Ste 2, Long Beach, CA 90807 Phone: 562-424-0724 Fax: 562-424-8433 | |
Daniel Hoa, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 3943 E Anaheim St, Long Beach, CA 90804 Phone: 562-597-4500 |